FDA Approves Atacicept for IgA Nephropathy

The U.S. Food and Drug Administration (FDA) granted accelerated approval to atacicept (Trutakna) on March 15, 2024, for the treatment of adults with primary IgA nephropathy who are at risk for disease progression. This marks the first-in-class approval for a drug targeting this specific kidney disease. Atacicept is designed to reduce proteinuria, a key indicator of kidney damage and disease severity.

The approval is supported by data from the ORIGIN 3 clinical trial, which demonstrated the efficacy of atacicept in reducing proteinuria. The drug is administered once weekly via self-injection. IgA nephropathy, also known as Berger's disease, is a chronic autoimmune kidney disease characterized by the buildup of immunoglobulin A (IgA) in the kidneys, leading to inflammation and potential kidney failure. The condition affects an estimated 1 in 2,500 people globally and is a leading cause of kidney disease requiring dialysis or transplantation.

Atacicept works by targeting B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), two cytokines that play a crucial role in the survival and maturation of B cells. By inhibiting these pathways, atacicept aims to reduce the production of pathogenic IgA antibodies and subsequent kidney inflammation. The accelerated approval pathway allows for earlier access to promising new treatments for serious conditions based on clinical trials showing a drug is reasonably likely to predict clinical benefit. Further clinical trials will be required to confirm the drug's clinical utility and long-term safety profile.